EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia

Aziz Farhat iD, Georgina El Hajjar, Hagop Kantarjian iD, Koji Sasaki iD, Nicholas J Short iD, Branko Cuglievan, Sanam Loghavi, Keyur Patel, Alex Bataller iD, Wei Ying Jen, Musa Yilmaz, Guillermo Montalban-Bravo iD und 10 weitere

Cancer · 15.08.2026 · 132 (16)

DOI: 10.1002/cncr.70568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 13.08.2026. Verfasst von Aziz Farhat und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Mutation, Nuclear Proteins, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute Cancer Center Support, Andrew Sabin Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nucleophosmin 1‐mutated ( NPM1mt ) acute myeloid leukemia (AML) is associated with a relatively favorable prognosis though long‐term outcomes remain suboptimal without clear predictors identified by therapy.

Methods

In a retrospective analysis, the authors identified 396 patients (18%) with newly diagnosed (ND) NPM1mt AML treated at The University of Texas MD Anderson Cancer Center and analyzed their outcomes. Using a Cox regression model, they analyzed predictors of survival in newly diagnosed NPM1mt AML across various therapies.

Results

Those treated with high intensity chemotherapy had a median overall survival (OS) of 84.7 months with a 5‐year rate of 53% (95% CI, 44%–61%) whereas those treated with a combination of a hypomethylating agent (HMA) and venetoclax had a median OS of 23.3 months with a 5‐year rate of 19% (95% CI, 5%–39%). The combination of cladribine, low‐dose cytarabine, and venetoclax alternating with azacitidine and venetoclax yielded better survival compared with HMA and venetoclax in an age‐matched analysis (5‐year OS rate of 74% vs. 24%) ( p = .048).

Conclusion

Among patients with NPM1mt treated with high‐intensity chemotherapy, older age, a poor performance status, and presence of a FLT3‐ITD mutation or extramedullary disease predicted a worse overall survival. For patients treated with a hypomethylating agent and venetoclax, older age was the only predictor of worse long‐term outcomes. These findings can be used for risk‐stratification of newly diagnosed NPM1mt AML and provide benchmarks of response and survival for this subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMutationNuclear ProteinsAntineoplastic Combined Chemotherapy ProtocolsHumansNucleophosminFemaleBridged Bicyclo Compounds, HeterocyclicRetrospective StudiesMiddle AgedAgedMaleAdultPrognosisSulfonamidesAzacitidineCytarabineAged, 80 and overCladribineYoung Adult

Stichwörter der Autor:innen

acuteazacitidinecladribinecytarabineleukemiamutationmyeloidnucleophosminprognosisretrospective studiesvenetoclax

Substanzen

NPM1 protein, humanNucleophosminBridged Bicyclo Compounds, HeterocyclicNuclear ProteinsvenetoclaxSulfonamidesAzacitidineCytarabineCladribine

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Aziz Farhat, Hagop Kantarjian, Koji Sasaki, Nicholas J Short, Alex Bataller, Guillermo Montalban-Bravo, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Tapan Kadia, Guillermo Garcia-Manero, Courtney D DiNardo

Förderung

  • NCI NIH HHS
  • National Cancer Institute Cancer Center Support
  • Andrew Sabin Family Foundation
  • Faculty Scholar Award at the University of Texas MD Anderson Cancer Center

Zitieren

APA

Farhat, A., El Hajjar, G., Kantarjian, H., Sasaki, K., Short, N. J., Cuglievan, B., Loghavi, S., Patel, K., Bataller, A., Jen, W. Y., Yilmaz, M., Montalban-Bravo, G., Hammond, D., Pemmaraju, N., Daver, N., Ravandi, F., Jabbour, E., Kadia, T., Borthakur, G., …, & Issa, G. C. (2026). Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia. Cancer, 132(16). https://doi.org/10.1002/cncr.70568

Vancouver

Farhat A, El Hajjar G, Kantarjian H, Sasaki K, Short NJ, Cuglievan B, et al. Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia. Cancer. 2026;132(16). doi:10.1002/cncr.70568

BibTeX
@article{Farhat2026,
  author = {Farhat, Aziz and El Hajjar, Georgina and Kantarjian, Hagop and Sasaki, Koji and Short, Nicholas J and Cuglievan, Branko and Loghavi, Sanam and Patel, Keyur and Bataller, Alex and Jen, Wei Ying and Yilmaz, Musa and Montalban-Bravo, Guillermo and Hammond, Danielle and Pemmaraju, Naveen and Daver, Naval and Ravandi, Farhad and Jabbour, Elias and Kadia, Tapan and Borthakur, Gautam and Garcia-Manero, Guillermo and DiNardo, Courtney D and Issa, Ghayas C},
  title = {Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {16},
  doi = {10.1002/cncr.70568}
}
Kostenlos starten →